Our portfolio companies are making headlines by changing the life of patients. Stay up-to-date on their latest news.
- Epics Therapeutics Initiates First-in-Human Studies with EP282, an oral Investigational Drug for the treatment of gastrointestinal inflammatory disorders and cancer
- PRISM、Roche社とGenentech社と共同研究・ライセンス契 約を締結
- Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)
- ACTICOR BIOTECH announces its projected IPO on the Euronext Growth® market in Paris
- ニュートン・バイオキャピタル、株式会社PRISM BioLabに新規投資
- Newton Biocapital invests in PRISM BioLab to support development of a unique peptide mimetic technology platform to discover new drugs for intractable diseases
- Newton Biocapital invests in EditForce to support development of a unique DNA/RNA editing platform based on PPR protein technology
- Newton Biocapital invests in NeuVasQ: EUR 20 million Series A to develop unique blood-brain barrier therapy
- Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers.
- SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
- Newton Biocapital invests in Flemish start-up DeuterOncology
- Newton Biocapital I invests in Perseus Proteomics Inc. in Japan to develop therapeutic antibodies for the treatment of blood cancers
- Sequana Medical announces positive interim data from North American pivotal alfapump® study (POSEIDON)
- Sequana Medical announces strong interim results from RED DESERT alfapump® DSR study and provides business update
- ACTICOR BIOTECH ANNOUNCES THE SUCCESS OF THE FIRST PHASE OF ITS ACTIMIS STUDY WITH GLENZOCIMAB IN PATIENTS WITH ACUTE ISCHEMIC STROKE
- ジェイファーマ株式会社 総額 17 億 4 千 6 百万円の資金調達完了
- J-Pharma Raises 1,746 million JPY in Funding
- SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 19.0 MILLION IN AN EQUITY PLACEMENT
- Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients
- Sequana Medical appoints leading experts as Heart Failure Scientific Advisors
- Sequana Medical announces unconditional IDE approval from U.S. FDA to start alfapump® pivotal study (POSEIDON)
- SEQUANA MEDICAL announces inclusion of alfapump® in German treatment guidelines (DGVS) for complications of liver cirrhosis
- Sequana Medical announces acceptance of late-breaking abstract of DSR therapy for volume overload in heart failure at Heart Failure 2019 Congress
- EditForce raises 870 million JPY
- エディットフォース株式会社 総額 8 億 7 千万円の資金調達完了
- Sequana Medical raises €27.5 million in successful Initial Public Offerin
- Sequana Medical announces the Coverage of the Base Offering of Its Initial Public Offering on Euronext Brussels
- Sequana Medical Launches Its Initial Public Offering on Euronext Brussels
- Sequana Medical receives Breakthrough Device designation from the FDA for its alfapump®
- 株式会社日本政策投資銀行（DBJ）日欧アーリーステージ医薬品のベンチャーキャピタル Newton Biocapital I pricaf privée SAへの出資契約を締結
- DBJ Signs Contract with Newton Biocapital I Pricaf Privee SA, a Japanese-European Venture Capital Fund for Early Stage Pharmaceuticals
- EPICS Therapeutics to Acquire Ogeda former assets, Adding Drug Discovery & Development Capabilities
- UK NICE recommends use of the alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements
- SEQUANA MEDICAL establishes new corporate headquarters in Ghent, Belgium and raises €8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders
- ACTICOR BIOTECH raises € 15.3 M in a Series B financing
- CHROMACURE S.A., a spin-off from the Université libre de Bruxelles (ULB),is launched with €17m committed equity investment to develop enhanced cancer therapies
- SYNERGIA raises €8.1 million in Series A
- ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE
J-Pharma Raises 1,746 million JPY in Funding
July 30, 2020
J-Pharma Co., Ltd. Yoshinori Bamba, Director, Corporate Planning Dept. Tel: 045-506-1155 firstname.lastname@example.org
Company Name: Contact:
J-Pharma Raises 1,746 million JPY in Funding
Yokohama, Japan, July 30th 2020 – J-Pharma Co., Ltd. (“J-Pharma”) has announced that it has raised 1,746 million JPY (16.32 million US dollars) as of July 30, 2020 from sixteen (16) new and existing investors in the Series D round, as described below.
From its establishment in 2005, J-Pharma, a clinical stage bio-venture company with a special focus on membrane transporters, has been conducting an array of unique drug developments by Hitoshi Endou, MD., Ph.D., formerly a professor of Kyorin University Faculty of Medicine. Recently J-Pharma has been placing the highest priority on the clinical development of its original inhibitors of L-type amino acid transporter 1 (“LAT1”) for the treatment of advanced cancer patients who failed to benefit from standard chemotherapy.
In this round, J-Pharma has been supported by 16 investors including Newton Biocapital I, S.A., a Belgium-based Venture Capital Fund (“Newton Biocapital”), SPERA PHARMA
, Inc., an IWAKI Group firm, (“SPERA”), and Ohara Pharmaceutical Co., Ltd., , (“Ohara Pharmaceutical”).
By taking full advantage of the broad networks and deep expertise possessed by these corporations, J-Pharma is endeavoring to develop JPH203 for the treatment of refractory advanced biliary tract cancer, OKY-034 for the treatment of refractory advanced pancreatic cancer and LAT1 inhibitors for the treatment of autoimmune diseases. J-Pharma will continue to focus on the research and development of its own proprietary, innovative medicines in areas with high unmet medical needs in collaboration with leading research institutions around the world and to prove the clinical usefulness of these medicines through strictly controlled clinical studies.
Max Yoshitake, President & CEO of J-Pharma commented, “In the middle of the COVID-19
pandemic, investments by domestic and overseas venture capital firms, as well as by pharmaceutical companies with deep expertise, clearly show that our company’s fundamental drug development strategy with a special focus on membrane transporters, particularly LAT1, is highly regarded as an unique and valuable approach. By utilizing this fund, we must strive to the utmost to carry out well-controlled clinical studies of our original compounds inhibiting LAT1, a molecular target discovered by Dr. Endou, to prove the clinical usefulness of these compounds. Our ultimate goal is to deliver these medicines to patients with diseases for which there is no cure as soon as possible.”
Dr. Toshiyuki Mori, Investment Partner of Newton Biocapital, commented. “As Newton Biocapital’s second investment project in Japan, we are extremely pleased to have invested in J- Pharma. LAT1 is a unique, distinguished, and attractive molecular target not only for oncology but also for autoimmune diseases. By involving Newton Biocapital’s experienced members in drug R&D and our global business development experts, we are assisting J-Pharma in delivering novel medicines to patients with diseases for which there is no cure as soon as possible. We look forward to contributing to the further expansion of J-Pharma’s business.”
Mr. Toshio Yoshioka, President of SPERA, commented, “The IWAKI Group has been involved in a full-range of pharmaceutical business from the development, manufacturing and sales of active pharmaceutical ingredients (APIs), to the development and sales/marketing of final pharmaceutical products. Among the affiliated companies of the IWAKI Group, SPERA is specialized in chemistry, manufacturing, and control (CMC) and providing pharmaceutical, bio- venture companies and academic research institutions with innovative solutions relating to drug R&D and manufacturing. I sincerely hope that our investment will contribute to the further progress of clinical developments at J-Pharma and serves as a milestone to explore the mutually, beneficial relationship between J-Pharma and the IWAKI Group.”
Dr. Seiji Ohara, President of Ohara Pharmaceutical, not only a major investor in the Series D round but also a business partner with respect to JPH203 in Japan, Asia and Africa, commented, “Ohara Pharmaceutical’s strategic focus has been to develop orphan drugs such as pediatric oncology products with the key objective of ‘addressing unmet medical needs.’ Challenging the development of treatment options for liver cirrhosis, biliary tract cancer (BTC) and pancreatic cancer is critical for the continuation and development of our business strategy to develop products which address unmet medical needs. J-Pharma’s development of the world’s first LAT1 inhibitor, JPH203, is an attractive opportunity to help patients suffering from end-stage BTC, and we sincerely hope that our investment will contribute to bringing this innovative new drug to
patients. Furthermore, as a global business partner to J-Pharma, Ohara Pharmaceutical will work closely with J-Pharma to accelerate the development and launch of JPH203 in Japan, then expand access of this critical treatment alternative to patients in regions such as Asia and Africa.”
- - Newton Biocapital I, S.A.
- - SPERA PHARMA, Inc.
- - Ohara Pharmaceutical Co., Ltd.
- - OSAKA University Venture Capital Co., Ltd. (OUVC)
- - Mitsubishi UFJ Capital Co., Ltd.
- - SRD Co., Ltd.
- - QB Capital, LLC
- - MBL Venture Capital Co., Ltd.
- - Iwagin Jigyo Souzou Capital Co., Ltd.
- - KNC Laboratories Co., Ltd.
- - SASEI CAPITAL INVESTMENT Co., Ltd.
- - Mizuho Capital Co., Ltd.
- - KISCO CO., LTD.
- - Nippon Venture Capital Co., Ltd. (NVCC)
- - KSP, Inc.
- - Fidea Capital, Ltd.
Location Representative Director Business Activities Capital
Establishment Company Homepage
J-Pharma Co., Ltd.
75-1 Onocho, Tsurumi-ku, Yokohama, Kanagawa Max Yoshitake, President & CEO Pharmaceutical Research & Development
50 million JPY (as of May 31, 2020)
26 December 2005 http://www.j-pharma.com
About JPH203 and OKY-034
JPH203 is J-Pharma’s original small molecule competitively inhibiting amino acid binding pocket of LAT1 which expresses on the cell membrane when a cell needs huge amounts of energy due to rapid proliferation and/or activation. JPH203 is the first LAT1-targeted compound undergoing
clinical studies and will become the first-in-class medicine if approved by competent authorities. J-Pharma confirmed its tolerability and preliminary efficacy in advanced solid cancer patients through a Phase 1 study, also discovered a biomarker capable of distinguishing a patient sub- population which would have less adverse events and to be more susceptible to JPH203. Using this biomarker as a companion diagnostic, JPH203 is now undergoing a Phase 2 clinical study for the treatment of advanced biliary tract cancer patients who failed to benefit from standard chemotherapy.
OKY-034 is a novel small molecule allosterically binding the LAT1 and holding the amino acid up-taking movements. J-Pharma executed a world-wide, exclusive license (with sub-license) agreement with Osaka University and KNC Laboratories Co., Ltd., both of which possess the composition patent for OKY-034. At Osaka University, a physician-sponsored Phase 1/2a clinical study of OKY-034 is underway for the treatment of advanced, unresectable pancreatic cancer patients who failed to benefit from standard chemotherapy.
About Newton Biocapital
Brussels, Belgium; Alain Parthoens, Managing Partner
Newton Biocapital is a Venture Capital Fund incorporated in Belgium, focused on financing
biotech and life science projects in the “core of Europe” (B, NL, D, F) and Japan for the
prevention and treatment of chronic diseases. The fund’s approach as lead investor is to support promising start-up projects as well as neglected or undervalued late-stage projects, in order to mitigate the risks and to create investor value. The leadership team consists of specialists with long-standing management and investor experience who coach bio-entrepreneurs through the development stages of their projects. Newton Biocapital’s mission is to generate substantial financial and societal value by providing innovative, breakthrough, and affordable solutions to patients
About SPERA PHARMA Co., Ltd.
SPERA was spun out from Takeda Pharmaceutical Company Limited (Takeda), and has taken over its part of CMC-related business unit on July 1, 2017. Subsequently, on March 2, 2020, Iwaki & Co., Ltd (listed as “Iwaki” on the First Section of the Tokyo Stock Exchange) acquired all the shares of SPERA in order to expand its R&D-oriented business in the fields of fine chemical and pharmaceuticals. SPERA has about 250 employees, including researchers and technical specialists in process chemistry, formulation and analysis, who worked for Takeda CMC with a wealth of experience in the R&D and manufacture of new drugs as well as LCM programs. They
have been engaged in contract R&D of pharmaceuticals as a partner company, supporting the pharmaceutical industry including Takeda, ventures and academia.
About Ohara Pharmaceutical Co., Ltd.
Ohara Pharmaceutical Co., Ltd. is a pharmaceutical company focused on the development and marketing of orphan drugs mainly in the field of pediatric oncology and on the development, manufacture, and marketing of generic drugs with innovative procedures taken to prevent medical accidents during use. In the current environment where innovative technology and medicines are improving clinical outcomes and altering existing medical practices, Ohara is expanding its business to look for innovation not only in treatment options, but also in areas such as prevention, diagnostics and patient care, which impacts the overall quality of healthcare. Ohara is aiming to become a company capable of providing “Total Healthcare Solutions” to patients.